[클리니컬 히스토리] 유한양행, 반환 MASH 신약 재LO 성공할까

Yuhan Corporation is revitalizing YH25724, a MASH candidate returned by Boehringer Ingelheim, by leveraging promising Phase 1 data that showed significant liver fat reduction. This move highlights a strategic shift toward internal clinical development to maximize pipeline value for potential re-licensing in the competitive metabolic disease market.